Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Tianjin Medical University Cancer Institute and Hospital

Reviewed by TrialFinderData Editorial Team · Updated

6 clinical trials · 6 recruiting · OTHER

Tianjin Medical University Cancer Institute and Hospital has 6 clinical trials registered on ClinicalTrials.gov, with 6 actively recruiting participants. The trials listed below cover 10 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Tianjin Medical University Cancer Institute and Hospital\'s Trial Portfolio

Tianjin Medical University Cancer Institute and Hospital is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

6 of Tianjin Medical University Cancer Institute and Hospital's 6 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Tianjin Medical University Cancer Institute and Hospital's research footprint spans Breast Cancer (1 trials), evaluating-the-efficacy-of-trop-2-adc-combination-therapy-in-advanced-triple-negative-breast-cancer (1), and Metastatic Pancreatic Cancer (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Phase 2 is the largest single phase in Tianjin Medical University Cancer Institute and Hospital's portfolio at 83% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Tianjin Medical University Cancer Institute and Hospital

RECRUITINGPhase 2NCT06498154

Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

Phase II multicenter prospective study on the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 2001 location
Breast Cancer
RECRUITINGPhase 2NCT06878625

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 - ADC joint PD - 1 single or...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 1381 location
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
RECRUITINGPhase 2NCT06951997

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 331 location
Metastatic Pancreatic Cancer
RECRUITINGNCT06702566

The Effect of Serum Ferritin in irAE

This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 15001 location
Immune-related Adverse EventMalignant Solid TumorsAcute Leukemia+1
RECRUITINGPhase 2NCT06560528

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced...

The efficacy and safety of combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for perioperative treatment of locally advanced gastric cancer with HER2...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 402 locations
Gastric CancerGastroesophageal Junction Adenocarcinoma
RECRUITINGPhase 2NCT06061146

Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma. Aim to find the difference in efficacy and safety between...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 1361 location
Esophageal Cancer

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Tianjin Medical University Cancer Institute and Hospital have on ClinicalTrials.gov?

Tianjin Medical University Cancer Institute and Hospital has 6 clinical trials registered on the federal ClinicalTrials.gov registry, of which 6 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Tianjin Medical University Cancer Institute and Hospital study?

Tianjin Medical University Cancer Institute and Hospital's registered trials cover 10 conditions on ClinicalTrials.gov, led by Breast Cancer (1 trial), evaluating-the-efficacy-of-trop-2-adc-combination-therapy-in-advanced-triple-negative-breast-cancer (1 trial), Metastatic Pancreatic Cancer (1 trial), immune-related-adverse-event (1 trial), Malignant Solid Tumors (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Tianjin Medical University Cancer Institute and Hospital clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 6 trials tracked for Tianjin Medical University Cancer Institute and Hospital.